Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Capio Biosciences logo — company profile

Capio Biosciences

Founded 2015 United States Madison, United States 4 employees Series A Total: $2.90M Biotechnology, Health Care

General Information

Company Name Capio Biosciences
Founded Year 2015
Location United States Madison, United States
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Capio Biosciences. To contact Capio Biosciences, visit capiobiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Capio Biosciences compare?

A PDF of Capio Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Capio Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Capio Biosciences

Capio Biosciences is a US-based biotech startup founded in 2015 by Seungpyo Hong PhD and Andrew Wang MD. The company's vision is to become the world's leading liquid biopsy company, providing valuable clinical information to improve patient outcomes. Capio Biosciences is committed to delivering high-value oncology diagnostics through its advanced platform called CapioCyte™, designed for the capture of circulating tumor cells (CTCs) from whole blood. CapioCyte™ utilizes biomimetic cell rolling and dendrimer-mediated multivalent cell capture, providing significantly greater capture sensitivity than other available platforms. It also offers enriched CTCs for post-capture molecular analysis such as FISH, RNA-Seq, and NGS. This innovative technology aligns with the current needs of cancer research and holds potential for clinical patient management in the future. With its pioneering approach, Capio Biosciences is positioned to make a significant impact in the field of oncology diagnostics. As the company continues to advance its platform and contribute to improving patient care decisions and outcomes, it presents an attractive opportunity for venture capital investment.

Business keywords: liquid biopsy, oncology diagnostics, circulating tumor cells, biomimetic cell rolling, dendrimer-mediated capture, CTC capture sensitivity, molecular analysis, FISH, RNA-Seq, NGS, biotech startup, clinical patient management, cancer research, precision medicine, biomarker discovery

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $2.90M 1
Betta Pharmaceuticals
05 Jan 2017

Capio Biosciences Alternatives & Competitors

View All Alternatives
Capio Biosciences vs
Vortex Biosciences
Vortex Biosciences United States

Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary tumor and have...

Venture round
7 employees
Biotechnology, Health Care
Capio Biosciences vs
Cellsway
Cellsway United Kingdom

Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) fr...

5 employees
Biotechnology, Health Care
Capio Biosciences vs
GILUPI GmbH
GILUPI GmbH Germany

Advancing diagnostic procedures for precision medicine

Acquired
8 employees
Biotechnology, Health Care
View all alternatives

FAQ About Capio Biosciences

Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information to improve patient outcomes. Founded in 2015 by cofounders Seungpyo Hong PhD (UW, Madison WI) and Andrew Wang MD (UNC, Chapel Hill NC), Capio Biosciences is a biotech start-up focused on delivering h...
Capio Biosciences was founded in 2015.
Capio Biosciences is headquartered in Madison, United States.
Capio Biosciences operates in Biotechnology and Health Care. Its work centres on liquid biopsy, oncology diagnostics, circulating tumor cells and biomimetic cell rolling.
Capio Biosciences has approximately 4 employees.
Capio Biosciences has completed 1 funding round, raising a total of $2.90M. The latest funding stage is Series A.
Top alternatives and competitors to Capio Biosciences include Vortex Biosciences, Cellsway, GILUPI GmbH, ANGLE, GeneCast Biotechnology Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Capio Biosciences and Vortex Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Capio Biosciences, https://bouncewatch.com/company/capio-biosciences, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes